DME treatment gets the German green light

Article

Chronic diabetic macula oedema (DME) treatment Iluvien, developed by Alimera Sciences, has obtained marketing authorization in Germany.

Chronic diabetic macula oedema (DME) treatment Iluvien, developed by Alimera Sciences, has obtained marketing authorization in Germany.

The decision, made by the Federal Ministry of Health of Germany, follows the successful completion of the Decentralized Regulatory Procedure (DCP). Iluvien was given a positive outcome from six Concerned Member States including Austria, France, Germany, Italy, Spain and Portugal.

The sustained release intravitreal implant delivers sub-microgram levels of fluocinolone acetonide for as long as 36 months. Latest clinical trials demonstrate that 38% of DME patients experienced an improvement in best-corrected visual acuity of 15 letters or more on the ETDRS chart.

Professor Albert Augustin, professor and chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Germany, said, "Iluvien will be a timely and much needed addition to the German market. As the largest country in Europe with a growing incidence of diabetic macular oedema, it has more DME patients than any of the other six countries. The approval of ILUVIEN in Germany will have a significant impact for the many patients with this chronic, debilitating disease."

Dan Myers, president and CEO of Alimera Sciences, commented, "We are very pleased to receive German marketing authorization for Iluvien, our fifth of seven expected approvals in the European Union. Assuming the closing of our recently announced financing, we anticipate that we will launch Iluvien in Germany during the first quarter of 2013."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.